Cell Therapy News Volume 25.35 | Nov 25 2024

    0
    113







    2024-11-25 | CTN 25.33


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.35 – 25 November, 2024
    TOP STORY

    Pooled CRISPR Screens with Joint Single-Nucleus Chromatin Accessibility and Transcriptome Profiling

    Researchers developed MultiPerturb-seq, a high-throughput CRISPR screening platform with joint single-nucleus chromatin accessibility, transcriptome, and guided RNA capture using combinatorial indexing combined with droplet microfluidics to scale throughput and integrate all three modalities.
    [Nature Biotechnology]

    Abstract
    PUBLICATIONSListed by the impact factor of the journal

    Rational Design of Advanced Gene Delivery Carriers: Macrophage Phenotype Matters

    Scientists revealed that nucleic acid delivery efficacy in macrophages was influenced by phenotype: IL-4-treated “M2-like” macrophages with suppressed mammalian target of rapamycin complex 1 levels were harder-to-transfect than “M1-like” macrophages for mRNA and DNA.
    [Advanced Materials]

    Abstract

    AcrIIIA1 Is a Protein–RNA Anti-CRISPR Complex That Targets Core Cas and Accessory Nucleases

    The authors discovered and characterized AcrIIIA1, the first Type III-A specific anti-CRISPR protein. They showed that AcrIIIA1 bound to Csm2 within the Cas10-Csm effector complex and attenuated Cas10’s DNase activity and second messenger production.
    [Nucleic Acids Research]

    Full ArticleGraphical Abstract

    Single-Stranded DNA with Internal Base Modifications Mediates Highly Efficient Knock-In in Primary Cells using CRISPR-Cas9

    Scientists showed that single-stranded DNA (ssDNA) with chemical modifications in 12–19% of internal bases improved knock-in by 2–3-fold compared to end-modified ssDNA in airway basal stem cells, CD34+ hematopoietic cells, T cells, and endothelial cells.
    [Nucleic Acids Research]

    Full ArticleGraphical Abstract

    Solid Tumor Immunotherapy using NKG2D-Based Adaptor CAR T Cells

    T cells were engineered to co-express NKG2D with a fusion protein that comprised Dap10 joined to a Dap12 endodomain.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract

    MAGE-A4 pMHC-Targeted CAR-T Cells Exploiting TCR Machinery Exhibit Significantly Improved In Vivo Function while Retaining Antigen Specificity

    Researchers determined whether MAGE-A4 pMHC-targeted CAR-T cells using the T cell receptor machinery exhibited superior functionality without compromising antigen specificity.
    [Journal of Immunotherapy of Cancer]

    Full Article

    STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition

    Scientists explored combination therapy using CD8 T cells engineered to express constitutively active STAT5 with vaccines. CD8 T cells were transduced with a retrovirus encoding the mouse gp100 T cell receptor.
    [Molecular Cancer Therapeutics]

    Abstract

    PCRX-201, a Novel IL-1Ra Gene Therapy Treatment Approach for Low Back Pain Resulting from Intervertebral Disc Degeneration

    When transduced with PCRX-201, the production and release of IL-1Ra was increased in degenerate human nucleus pulposus cells and tissue.
    [Gene Therapy]

    Full Article
    Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
    REVIEWS

    Resistance to Immunomodulatory Drugs in Multiple Myeloma: The Cereblon Pathway and Beyond

    The authors provide a comprehensive overview of the existing work on immunomodulatory drugs resistance in multiple myeloma, focusing specifically on the emerging evidence of CRBN pathway-independent mechanisms.
    [Haematologica]

    Abstract
    INDUSTRY AND POLICY NEWS

    Vyriad Announces Strategic Collaboration with Novartis to Develop In Vivo CAR-T Cell Therapies

    Vyriad, Inc. announced a strategic collaboration with Novartis to discover and develop in vivo CAR T-cell therapies.
    [Vyriad, Inc.]

    Press Release

    US FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product

    StemCyte Inc. announced that the US FDA has approved the Biologics License Application for its HPC, Cord Blood product REGENECYTE™, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders.
    [StemCyte, Inc.]

    Press Release
    FEATURED EVENT

    Advanced Therapies Week 2025

    January 20-23, 2025

    Dallas, Texas, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – CAR T Cell Therapy Development

    City of Hope – Duarte, California, United States

    Faculty Position – Translational Cancer Research

    Northwell Health – Manhasset, New York, United States

    Doctoral Student – Stem Cells and Cancer Stem Cell Regulation

    University of Lund – Lund, Sweden

    Postdoctoral Positions – Blood Cancer and Cell Therapy Research

    University of Ostrava – Ostrava, Czech Republic

    Group Leader Positions – Gene Therapy

    GeneT, University of Coimbra – Coimbra, Portugal

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2